{"cluster": 63, "subcluster": 19, "abstract_summ": "Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials.Although many clinical trials are already underway and the majority of patients have received antiviral therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven to be effective currently.There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19.In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19.The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a \u201cPublic Health Emergency of International Concern\u201d (PHEIC).As pathological examination has confirmed the involvement of immune hyperactivation and acute respiratory distress syndrome in fatal cases of COVID-19, several disease-modifying anti-rheumatic drugs (DMARDS), such as hydroxychloroquine and tocilizumab, have been proposed as potential therapies for the treatment of COVID-19.", "title_summ": "Old and re-purposed drugs for the treatment of COVID-19.Anti COVID-19 Drugs: Need for More Clinical Evidence and Global ActionCurrent targeted therapeutics against COVID-19: based on first-line experience in chinaCOVID-19 and therapeutic drugs repurposing in hand: the need for collaborative effortsThe Rationale for Potential Pharmacotherapy of COVID-19Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID\u201019The immunology of COVID-19: is immune modulation an option for treatment?Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2:Considerations Regarding Therapeutic Drug Monitoring and Drug\u2013Drug Interactions", "title_abstract_phrases": "Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials.In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19.Anti COVID-19 Drugs: Need for More Clinical Evidence and Global ActionThe World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a \u201cPublic Health Emergency of International Concern\u201d (PHEIC).Although many clinical trials are already underway and the majority of patients have received antiviral therapy based on medication experience with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and preliminary results from some clinical trials, there are no antiviral drugs proven to be effective currently.There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19.In this narrative perspective review, we addressed evidence-based literature on various possible antiviral medications, plant-derived antivirals drugs, and other valuable treatment options for COVID-19 management."}